C
TG Therapeutics, Inc. TGTX
$33.78 -$0.77-2.23% NASDAQ
Recommendation
Prev Close
$33.78
Volume
105
Avg Vol (90D)
2,002,066
Market Cap
$4.93B
Dividend & Yield
--
52-Week Range
$22.92 - $46.48
P/E (TTM)
91.35
EPS (TTM)
$0.37
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
TG Therapeutics (TGTX, $33.78) entered Downtrend as Momentum indicator drops below 0 level on Oct 29, 2025
10/30/2025 - Tickeron - Stocks
TG Therapeutics (TGTX, $34.55) entered Uptrend as Momentum indicator ascends above 0 level on Oct 28, 2025
10/29/2025 - Tickeron - Stocks
TG Therapeutics (TGTX, $34.55) Stochastic Oscillator left the oversold zone on October 28, 2025
10/29/2025 - Tickeron - Stocks
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates
10/28/2025 - Zacks Investment Research
Top Research Reports for NVIDIA, SAP & American Express
10/28/2025 - Zacks Investment Research
Does Single-Infusion BRIUMVI Trial Completion Reset the Competitive Narrative for TG Therapeutics (TGTX)?
10/28/2025 - Simply Wall St
Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline
10/28/2025 - Zacks Investment Research
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified ...
10/28/2025 - GuruFocus
TG Therapeutics completes enrollment in Phase 3 ENHANCE trial
10/28/2025 - The Fly
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
10/28/2025 - Globe Newswire
GWN Securities Inc. Acquires 26,884 Shares of TG Therapeutics, Inc. $TGTX
10/28/2025 - MarketBeat
TG Therapeutics (TGTX, $33.69) Stochastic Oscillator left the oversold zone on October 27, 2025
10/28/2025 - Tickeron - Stocks
TG Therapeutics' BRIUMVI Study: Real-World Insights for RMS Treatment
10/27/2025 - TipRanks Financial Blog
TG Therapeutics' BRIUMVI Breast Milk Study: Key Insights for Investors
10/27/2025 - TipRanks Financial Blog
TG Therapeutics' Promising Phase 1 Study on Azer-cel for Autoimmune Disorders
10/27/2025 - TipRanks Financial Blog
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release
10/27/2025 - Zacks Investment Research
TG Therapeutics (TGTX) to Release Quarterly Earnings on Monday
10/27/2025 - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Receives "Hold (C-)" Rating from Weiss Ratings
10/26/2025 - MarketBeat
First Citizens Bank & Trust Co. Raises Position in TG Therapeutics, Inc. $TGTX
10/26/2025 - MarketBeat
Sector Gamma AS Grows Position in TG Therapeutics, Inc. $TGTX
10/24/2025 - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt
10/23/2025 - Simply Wall St
Envestnet Portfolio Solutions Inc. Takes $543,000 Position in TG Therapeutics, Inc. $TGTX
10/22/2025 - MarketBeat
Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $49.00
10/19/2025 - Ticker Report
TG Therapeutics (TGTX) Gets a Sell from Bank of America Securities
10/17/2025 - TipRanks Financial Blog
TG Therapeutics (TGTX, $35.05) Stochastic Oscillator left the oversold zone on October 15, 2025
10/16/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$454.07M
EBITDA (TTM)
$85.89M
EBIT (TTM)
$85.85M
Net Income (TTM)
$60.46M
Balance Sheet
Total Assets (Q)
$702.61M
Total Debt (Q)
$254.53M
Total Liabilities (Q)
$426.18M
Book Value Per Share (Q)
$1.90
Cash Flow
Cash from Operations (TTM)
-$59.13M
Cash from Investing (TTM)
-$10.47M
Cash from Financing (TTM)
$115.84M
Net Change in Cash (TTM)
$46.24M
Filings
Filing Date
Friday, August 8, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
1.62
7-Day Total Return
-4.09%
30-Day Total Return
3.59%
60-Day Total Return
21.95%
90-Day Total Return
-9.44%
Year to Date Total Return
8.76%
1-Year Total Return
34.42%
2-Year Total Return
357.10%
3-Year Total Return
480.41%
5-Year Total Return
33.68%
52-week Low
Nov 04, 2024 - $22.92
52-week High
May 01, 2025 - $46.48
Valuation
Market Cap
$4.93B - Mid Cap
Enterprise Value
$4.93B
Price/Sales (TTM)
12.09
Price/Book (Q)
17.75
Dividends and Shares
Shares Outstanding
162.56
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tgtherapeutics.com
Phone Number
212 554 4484
Address
3020 Carrington Mill Blvd.
Morrisville, NC 27560
Country
United States
Year Founded
1993
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United... more
NASDAQ 10/29/2025 4:00PM Eastern Quotes delayed